MRA(Tocilizumab)

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Polyarticular Juvenile Idiopathic Arthritis

Conditions

Polyarticular Juvenile Idiopathic Arthritis

Trial Timeline

Feb 1, 2005 → Jun 1, 2009

NCT ID

NCT00144625

About MRA(Tocilizumab)

MRA(Tocilizumab) is a phase 3 stage product being developed by Chugai Pharmaceutical for Polyarticular Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00144625. Target conditions include Polyarticular Juvenile Idiopathic Arthritis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00380601	Phase 3	Completed	May 1, 2006	Feb 1, 2009	Rheumatoid Arthritis
NCT00144586	Phase 3	Completed	Mar 1, 2005	Jun 1, 2009	Rheumatoid Arthritis
NCT00144625	Phase 3	Completed	Feb 1, 2005	Jun 1, 2009	Polyarticular Juvenile Idiopathic Arthritis
NCT00144560	Pre-clinical	Completed	Feb 1, 2005	Aug 1, 2005	Rheumatoid Arthritis
NCT00144573	Pre-clinical	Completed	Jan 1, 2005	Oct 1, 2005	Rheumatoid Arthritis
NCT00144664	Phase 3	Completed	Nov 1, 2004	Oct 1, 2005	Systemic Juvenile Idiopathic Arthritis
NCT00144612	Phase 3	Completed	Jul 1, 2004	Jun 1, 2009	Systemic Juvenile Idiopathic Arthritis
NCT00144547	Phase 3	Completed	Apr 1, 2004	Jun 1, 2009	Rheumatoid Arthritis
NCT00144651	Phase 2	Completed	Aug 1, 2001	Jun 1, 2009	Rheumatoid Arthritis

Competing Products

2 competing products in Polyarticular Juvenile Idiopathic Arthritis

See all competitors

Product	Company	Stage	Hype Score
Abatacept	Bristol Myers Squibb	Phase 3	76
Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)	UCB	Phase 3	74

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved

Pegasys® + Pegasys®Approved

ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3

R744 + Epoetin betaPhase 3

EmicizumabPhase 3